Health & Fitness
Tue, August 23, 2011Mon, August 22, 2011Sat, August 20, 2011Fri, August 19, 2011Thu, August 18, 2011Wed, August 17, 2011Tue, August 16, 2011Mon, August 15, 2011Fri, August 12, 2011Thu, August 11, 2011Wed, August 10, 2011Tue, August 9, 2011Mon, August 8, 2011Sun, August 7, 2011Sat, August 6, 2011Fri, August 5, 2011Thu, August 4, 2011Wed, August 3, 2011Tue, August 2, 2011Mon, August 1, 2011Sun, July 31, 2011Fri, July 29, 2011Thu, July 28, 2011Wed, July 27, 2011Tue, July 26, 2011Mon, July 25, 2011Sat, July 23, 2011Fri, July 22, 2011Thu, July 21, 2011Wed, July 20, 2011Illumina Announces New $100 Million Share Repurchase Authorization
Published in Health and Fitness on Thursday, August 4th 2011 at 1:23 GMT by Market Wire
SAN DIEGO--([ BUSINESS WIRE ])--Illumina (Nasdaq:ILMN) today announced that on August 1, 2011, its Board of Directors authorized the Company to repurchase, on a discretionary basis, up to $100 million of its outstanding common shares in the open market or in privately negotiated transactions, subject to market conditions and other factors. The previous discretionary $100 million share repurchase program authorized in July 2010 was completed this week.
"We believe that the repurchase of our common stock represents an effective use of our capital and underscores our commitment to maximize value for our shareholders"
aWe believe that the repurchase of our common stock represents an effective use of our capital and underscores our commitment to maximize value for our shareholders,a said Illuminaa™s Christian Henry, Senior Vice President, General Manager of Life Sciences and Chief Financial Officer. aSince 2008, we have bought over 12 million shares of our common stock through prior authorizations, returning nearly $450 million to shareholders. Through the Boarda™s new authorization, we expect to continue our share repurchase programs.a
About Illumina
Illumina ([ http://www.illumina.com ]) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
Forward-Looking Statements
This release contains forward-looking statements that involve risks and uncertainties, including statements we make regarding future discretionary share repurchases. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
